HERPES-ZOSTER MYELITIS

被引:126
作者
DEVINSKY, O
CHO, ES
PETITO, CK
PRICE, RW
机构
[1] CORNELL UNIV,MED CTR,NEW YORK HOSP,DEPT NEUROL,NEW YORK,NY 10021
[2] CORNELL UNIV,MED CTR,NEW YORK HOSP,DEPT PATHOL NEUROPATHOL,NEW YORK,NY 10021
[3] UNIV MED & DENT NEW JERSEY,NEW JERSEY MED COLL,DEPT PATHOL,NEWARK,NJ 07103
[4] MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021
关键词
D O I
10.1093/brain/114.3.1181
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We studied the clinical (10 patients) and pathological (9 patients) findings in 13 patients with herpes zoster myelitis, all of whom had systemic illnesses associated with immunosuppression. The median interval between the onset of the herpes zoster rash and myelopathic symptoms was 12 days, and the subsequent median interval to maximal deficit was 10.5 days. Presenting neurological symptoms were characteristically ipsilateral to the rash, with motor dysfunction predominating, followed by a spinothalamic and, less often, posterior column sensory deficit. Pathological involvement was most severe in the dorsal root entry zone and posterior horn of the spinal cord segment corresponding to the involved dermatome. There was variable spread both horizontally and vertically in the spinal cord. Direct varicella-zoster virus (VZV) infection of neuroectodermal cells, particularly oligodendrocytes, was demonstrated by immunostaining viral antigens (8 cases), and by the presence of Cowdry type A intranuclear inclusions (7 cases) and often was associated with focal demyelination (6 cases). In 4 patients a VZV vasculitis was associated with leptomeningitis and haemorrhagic necrosis (spinal cord in 1; brainstem or cerebellum in 3). The protracted evolution in many cases and the pathologically documented direct viral infection of the spinal cord provide a rational basis for the use of antiviral therapy in preventing or attenuating the evolving myelopathy.
引用
收藏
页码:1181 / 1196
页数:16
相关论文
共 44 条
[1]  
ALTROCCHI PAUL H., 1963, TRANS AMER NEUROL ASSOC, V88, P186
[2]  
BELLAVITIS C, 1931, REV NEUROLIGA, V4, P337
[3]  
Biggart JH, 1938, LANCET, V2, P944
[4]  
BOUDIN G, 1958, Rev Neurol (Paris), V99, P535
[5]  
BRUCE A, 1907, REV NEUROL PSYCHIAT, V5, P885
[6]   HERPES-ZOSTER MYELITIS TREATED SUCCESSFULLY WITH VIDARABINE [J].
CORSTON, RN ;
LOGSDAIL, S ;
GODWINAUSTEN, RB .
BRITISH MEDICAL JOURNAL, 1981, 283 (6293) :698-699
[7]   HERPES-ZOSTER MYELITIS TREATED WITH VIDARABINE [J].
CULLIS, PA ;
GILROY, J ;
CUSHING, R .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1982, 45 (01) :94-95
[8]  
Denny-Brown D., 1944, ARCH NEUROL AND PSYCHIAT, V51, P216
[9]   THROMBOTIC CEREBRAL VASCULOPATHY ASSOCIATED WITH HERPES-ZOSTER [J].
EIDELBERG, D ;
SOTREL, A ;
HOROUPIAN, DS ;
NEUMANN, PE ;
PUMAROLASUNE, T ;
PRICE, RW .
ANNALS OF NEUROLOGY, 1986, 19 (01) :7-14
[10]  
Force L, 1968, Mars Med, V105, P381